List of contributions Health Economics Conference 2025

WEDNESDAY, JUNE 18, 2025

KEYNOTE LECTURE (Auditorium 3)

Chair: Pierre Dubois (TSE, CEPR)

Liran Einav (Stanford University) 

“Health and Longevity in the US: Evidence and Implications" (with Amy Finkelstein) -> please email Liran <leinav@stanford.edu> for the slides

PARALLEL SESSION 1A - Healthcare Funding and Pricing (Auditorium 3)

Chair: Léa Bignon (TSE)

  • David Ridley (Duke University), Chenxi Xu (Duke University, CEPR) and Peng Sun (Duke University) “Optimal Push and Pull Funding for Global Health”

  • Luca Maini (Harvard University), Emma B. Dean (The Dartmouth Institute) and Josh Feng (University of Utah) “Stocking Under the Influence: Spillovers from Commercial Drug Coverage to Medicare Utilization”

  • Luis Sa (Nova School of Business & Economics), Pedro Pita Barros (Nova School of Business & Economics) and Giovanni Righetti (Nova School of Business & Economics) “Pricing Mechanisms for Multi-Indication Drugs”

PARALLEL SESSION 1B - Cost-Sharing, and Subsidies in Healthcare (Auditorium 4)

Chair: Santiago Ortiz (TSE)

  • Chiara Gardenghi (New York University) “Bundled Loyalty Discounts in Healthcare: Evidence from Physician-Administered Vaccines”

  • Martin Salm (Tilburg University) and Tobias J. Klein (Tilburg University, CEPR) “Is physician cost-sharing an alternative to patient cost-sharing?”

  • Gosia Majewska (ESSEC Business School, Paris) and Krzysztof Zaremba (Instituto Tecnologico Autonomo de Mexico) “Universal Subsidies in Pharmaceutical Markets: Lessons from Poland’s Drugs 75+ Policy”

PLENARY SESSION 1 - Innovation, Entry, and Price Regulation in Healthcare (Auditorium 3)

Chair: Angie Acquatella (TSE)

  • Rebekah Dix (MIT) and Todd Lensman (MIT) “Combining Complements: Theory and Evidence from Cancer Treatment Innovation”

  • Rena Conti (Boston University) and Rubaiyat Alam (Kansas State University) “Entry Delays and Fighting Brands: Evidence from Generics and Authorized Generics”

  • Yunan Ji (Georgetown University) and Parker Rogers (Indiana University) “The Long-Run Impacts of Regulated Price Cuts: Evidence from Medicare”

PARALLEL SESSION 2A - Management and Costs in Healthcare (Auditorium 3)

Chair: Charu Gupta (UCLA)

PARALLEL SESSION 2B - Physician Behavior (Auditorium 4)

Chair: Catarina Goulão (TSE)

  • Franziska Valder (University of Copenhagen) “Gender disparities in heart disease: individual and provider behavior”

  • Juan Pablo Atal (University of Pennsylvania), Tomas Larroucau (University of Arizona), Pablo Munoz (Universidad de Chile) and Cristobal Otero (Columbia Business School) “Physicians' Occupational Licensing and the Quantity-Quality Trade-off”

  • Lionel Wilner (CREST, Paris), Philippe Choné (CREST, Paris, CEPR) and Francis Kramarz (Collège de France, CEPR) “Physician labor supply, financial incentives, and healthcare accessibility”

POLICY ROUNDTABLE - Challenges for European Pharmaceutical Innovation Policy (Auditorium 3)

Chair : Jean Tirole (TSE, CEPR)

  • Pedro Pita Barros (Nova School of Business and Economics)

  • Tina Taube (EFPIA)

  • Jean Tirole (TSE, CEPR)

  • Adrian Towse (OHE UK) 


THURSDAY, JUNE 19, 2025

POLICY ROUNDTABLE - Policies against Antimicrobial Resistance (Auditorium 3)

Chair : Pierre Dubois (TSE, CEPR)

  • Pierre Dubois (TSE, CEPR)

  • Aleksandra Opalska (Directorate-General for Health and Food Safety, European Commission)

  • John Rex (AMR.Solutions - F2G Ltd)

  • Henry Skinner (CEO, AMR Action Fund) 

PARALLEL SESSION 3A - Plan Design and Hospital Reforms (Auditorium 3)

Chair: Valentina Reig (TSE)

  • Natalia Serna (Stanford University), Giancarlo Buitrago (Universidad Nacional de Colombia), Paul Rodríguez-Lesmes (Universidad del Rosario) and Marcos Vera-Hernández (University College London, CEPR) “Enrollee Reassignment Rules After Health Plan Terminations”

  • Benjamin Vatter (MIT), José Ignacio Cuesta (Stanford University) and Carlos Noton (PUC-Chile) “Vertical Integration and Plan Design in Healthcare Markets”

  • Angie Acquatella (TSE) and Victoria Marone (University of Texas at Austin) “The Risk Protection Value of Moral Hazard”

PARALLEL SESSION 3B - Price Controls and Regulation in Pharma (Auditorium 4)

Chair: Giulia Tani (TSE)

  • Harsh Gupta (Stanford University) and Shengmao Cao (Northwestern University) “Price Controls with Imperfect Competition and Choice Frictions: Evidence from Indian Pharmaceuticals”

  • Jiekai Zhang (Hanken School of Economics, Helsinki), Mikko Vanhala (University of Helsinki) and Markku Siikanen (VATT Research Institute) “Optimal Retail Pharmaceutical Pricing Policy”

  • Debi Prasad Mohapatra (University of Massachusetts, Amherst) and Pierre Dubois (TSE, CEPR) “Regulating Trade Margins and Consumer Welfare: Evidence from Cardiac Products in India”

KEYNOTE LECTURE (Auditorium 3)

Chair: Jean Tirole (TSE, CEPR)

Nikhil Agarwal (MIT)
“Human-AI Collaboration in Healthcare”

PARALLEL SESSION 4A - Physicians’ Incentives and Decisions (Auditorium 3)

Chair: Philippe De Donder (TSE)

PARALLEL SESSION 4B - Generics, Biosimilars, Vaccine Skepticism (Auditorium 4)

Chair: Xin Zhang (TSE)

PLENARY SESSION 2 - Bargaining and Competition (Auditorium 3)

Chair: Thierry Magnac (TSE)

  • Amanda Starc (Northwestern University), Aslihan Asil (Yale Law School), Paulo Ramos (University of Chicago) and Thomas G. Wollmann (University of Chicago) “Painful Bargaining Evidence from Anesthesia Rollups”

  • Riley League (University of Illinois, Urbana Champaign), Renuka Diwan (Boston University), Paul Eliason (University of Utah), Jetson Leder-Luis (Boston University), Ryan C. McDevitt (Duke University) and James W. Roberts (Duke University) “Competition and Fraud in Health Care“

  • Ashley Swanson (University of Wisconsin), Panle Jia Barwick (University of Wisconsin, CEPR) and Tianli Xia (University of Rochester) “A Double Dose of Reform: Insurance and Centralized Negotiation in Drug Markets”